TY - JOUR T1 - Contrasting the brain imaging features of MOG-Antibody disease, with AQP4- Antibody NMOSD and Multiple Sclerosis JF - medRxiv DO - 10.1101/2020.09.22.20198978 SP - 2020.09.22.20198978 AU - Silvia Messina AU - Romina Mariano AU - Adriana Roca-Fernandez AU - Ana Cavey AU - Maciej Jurynczyk AU - Maria Isabel Leite AU - Massimiliano Calabrese AU - Mark Jenkinson AU - Jacqueline Palace Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/23/2020.09.22.20198978.abstract N2 - Neuromyelitis optica associated with aquaporin-4-antibodies (NMOSD-AQP4) and myelin oligodentrocyte-glycoprotein antibody-associated disorder (MOGAD) have been recently recognised as different from multiple sclerosis.Although conventional MRI may help distinguish multiple sclerosis from antibody-mediated diseases, the use of quantitative and non-conventional imaging may give more pathological information and explain the clinical differences.We compared, using non-conventional imaging, brain MRI findings in 75 subjects in remission with NMOSD-AQP4, MOGAD, multiple sclerosis or healthy controls (HC). Volumetrics, white matter and cortical lesions, and tissue integrity measures using diffusion imaging, were analysed in the four groups along with their association with disability (expanded disability status scale [EDSS] and visual acuity).The volumetric analysis showed that, deep grey matter volumes were significantly lower in multiple sclerosis (p=0.0001) and MOGAD (p=0.02), compared to HC. Relapsing MOGAD had lower white matter, pallidus and hippocampus volumes than in monophasic (p<0.05).Optic chiasm volume was reduced only in NMOSD-AQP4 who had at least one episode of optic neuritis (ON) (NMOSD-AQP4-ON vs NMOSD-AQP4 p<0.001, HC p<0.001, MOGAD-ON p=0.04, multiple sclerosis-ON p=0.02) likely reflecting the recognised posterior location of NMOSD-AQP4-ON and its severity.Lesion volume was greatest in multiple sclerosis followed by MOGAD and in these two diseases, the lesion volume correlated with disease duration (multiple sclerosis R=0.46, p=0.05, MOGAD R=0.81, p<0.001), cortical thickness (multiple sclerosis R=-0.64, p=0.0042, MOGAD=-0.71, p=0.005) and deep grey matter volumes (multiple sclerosis R=-0.65, p=0.0034, MOGAD R=-0.93, p<0.001).Lesional-fractional anisotropy (FA) was reduced and mean diffusivity increased in all patients, but overall, FA was only reduced in the non-lesional tissue in multiple sclerosis (p=0.01), although focal reductions were noted in NMOSD-AQP4, reflecting mainly optic nerve and corticospinal tract pathways.Cortical/juxtacortical lesions were seen in a minority of MOGAD, while cortical/juxtacortical and purely cortical lesions were identified in the majority of multiple sclerosis and in none of the NMOSD-AQP4.Non-lesional FA in NMOSD-AQP4, lower white-matter volume and female sex in multiple sclerosis, and lower brainstem volume in MOGAD were the best predictors of EDSS disability (accounting for 46%, 49% and 19% respectively). Worse visual acuity associated with lower optic chiasm volume in NMOSD-AQP4 and lower thalamus volume in MOGAD (accounting for 58% and 35% respectively).Although MOGAD patients had good outcomes, deep grey matter atrophy was present. In contrast, NMOSD-AQP4 patients showed a relative sparing of deep grey matter volumes, despite greater residual disability as compared with MOGAD patients. NMOSD-AQP4 but not MOGAD patients showed reduced FA in non-lesional tissue.Competing Interest StatementDr Messina has received travel grants from Biogen, Novartis, Bayer, Merck, Almirall, Roche and honorarium for advisory work from Biogen. Dr Mariano is undertaking graduate studies funded by the Rhodes Trust and the Oppenheimer Memorial Trust. Ms Roca-Fernandez reports no disclosures. Ms Ana Cavey reports no disclosures. Dr Maciej Jurynczyk reports no disclosures. Dr Leite reported being involved in aquaporin 4 testing, receiving support from the National Health Service National Specialised Commissioning Group for Neuromyelitis Optica and the National Institute for Health Research Oxford Biomedical Research Centre, receiving speaking honoraria from Biogen Idec, and receiving travel grant from Novartis. Prof Palace is partly funded by highly specialised services to run a national congenital myasthenia service and a neuromyelitis service. She has received support for scientific meetings and honorariums for advisory work from Merck Serono, Biogen Idec, Novartis, Teva, Chugai Pharma and Bayer Schering, Alexion, Roche, Genzyme, MedImmune, EuroImmun, MedDay, Abide and ARGENX, and grants from Merck Serono, Novartis, Biogen Idec, Teva, Abide and Bayer Schering. Her hospital trust received funds for her role as clinical lead for the RSS, and she has received grants from the MS society and Guthie Jackson Foundation for research studies. Prof. Calabrese has served on scientific advisory boards for Biogen Idec, Genzyme, Merck Serono, Novartis and Roche and has received grants from Genzyme, Merck Serono, Novartis and Roche and travel and/or speaker honoraria from Merck Serono, Roche, Biogen Idec, Novartis and Genzyme. Prof. Jenkinson receives royalties from licensing of FSL to non-academic, commercial parties.Funding StatementWe thank the NHS Highly Specialised Commissioning Team for funding the Neuromyelitis Optica service in Oxford. MRI scans were funded by a Research and Development Fund belonging to the principal investigator, Professor Jacqueline Palace.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants signed informed, written consent specific to this study which was approved by the Research Ethics Committee of Cambridge South (project code REC 17/EE/0246). Additional clinical data were collected under the Neuromyelitis Optica Spectrum Disorders and MS research Tissue Bank study (favourable approval obtained by the South Central - Oxford C Research Ethics Committee, project code 16/SC/0224). Consent was obtained according to the Declaration of Helsinki. The reporting of this research was done in conjunction with the STROBE supporting guidelinesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is collected and stored in accordance with GDPR guidelines. Data availability is dependent on specific collaboration. Analysis software and methods are publicly available. ER -